Valuation: Bicycle Therapeutics plc

Market Cap 31Cr 27Cr 25Cr 23Cr 44Cr 2.94TCr 44Cr 298.2Cr 117.01Cr 1.44TCr 115.58Cr 113.07Cr 4.99TCr P/E 2026 *
-1.89x
P/E 2027 * -2.1x
Enterprise Value -20Cr -18Cr -17Cr -15Cr -29Cr -1.95TCr -29Cr -197.72Cr -78Cr -955.7Cr -77Cr -75Cr -3.31TCr EV / Sales 2026 *
-11.2x
EV / Sales 2027 * -6.82x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+5.50%
1 week+1.38%
Current month+4.01%
1 month+7.56%
3 months-10.73%
6 months-33.58%
Current year-37.71%
1 week 4.08
Extreme 4.075
4.52
1 month 3.92
Extreme 3.92
4.52
Current year 3.92
Extreme 3.92
7.34
1 year 3.92
Extreme 3.92
9.18
3 years 3.92
Extreme 3.92
28.67
5 years 3.92
Extreme 3.92
62.08
10 years 3.92
Extreme 3.92
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
06/07Sell

Chief Financial Officer

-104 0.0003%
06/07Sell

CHIEF PROD & SUPPLY CHAIN OFF

-255 0.0007%
06/07Sell

Chief Operating Officer

-376 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+5.50%+1.38%-44.88%-81.30% 31Cr
+1.84%-0.66%+59.82%+92.96% 5.49TCr
-4.14%-8.06%+58.96%+118.67% 5.46TCr
-2.24%+3.59%+17.75%+477.47% 2.51TCr
-1.60%-6.21%-18.96%-15.21% 2.31TCr
+2.43%+1.06%+42.44%-1.27% 1.99TCr
-3.19%0.00%+35.60%-26.98% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+51.91%+726.40% 1.57TCr
-1.05%+1.16%+25.95%+194.27% 1.42TCr
Average -0.06%-0.11%+42.37%+184.22% 2.42TCr
Weighted average by Cap. -0.89%-1.45%+51.14%+176.81%

Financials

2026 *2027 *
Net sales 1.82Cr 1.6Cr 1.48Cr 1.36Cr 2.58Cr 173.91Cr 2.63Cr 18Cr 6.93Cr 85Cr 6.85Cr 6.7Cr 295.36Cr 1.41Cr 1.24Cr 1.14Cr 1.06Cr 2Cr 134.59Cr 2.03Cr 14Cr 5.36Cr 66Cr 5.3Cr 5.18Cr 228.59Cr
Net income -15Cr -13Cr -12Cr -11Cr -22Cr -1.47TCr -22Cr -148.83Cr -58Cr -719.39Cr -58Cr -56Cr -2.49TCr -16Cr -14Cr -13Cr -12Cr -23Cr -1.55TCr -23Cr -157.23Cr -62Cr -760.02Cr -61Cr -60Cr -2.63TCr
Net Debt -51Cr -45Cr -41Cr -38Cr -72Cr -4.88TCr -74Cr -495.92Cr -194.59Cr -2.4TCr -192.22Cr -188.04Cr -8.29TCr -40Cr -35Cr -33Cr -30Cr -57Cr -3.85TCr -58Cr -391.47Cr -153.6Cr -1.89TCr -151.73Cr -148.43Cr -6.55TCr
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
10/26/10 $4.410 +5.50% 8,04,201
09/26/09 $4.180 -2.34% 5,77,309
08/26/08 $4.280 -2.28% 3,37,115
07/26/07 $4.380 +0.69% 5,07,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.410USD
Average target price
12.62USD
Spread / Average Target
+186.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock